Financiere des Professionnels Fonds d investissement inc. Has $11.41 Million Stock Holdings in Pfizer Inc. $PFE

Financiere des Professionnels Fonds d investissement inc. raised its position in Pfizer Inc. (NYSE:PFE) by 13.1% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 458,213 shares of the biopharmaceutical company’s stock after purchasing an additional 53,084 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in Pfizer were worth $11,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Horizon Financial Services LLC grew its holdings in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $25.61 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The stock has a market capitalization of $145.93 billion, a P/E ratio of 19.55 and a beta of 0.34. The stock has a fifty day moving average of $26.52 and a 200-day moving average of $26.32.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 EPS. Pfizer’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s payout ratio is 131.30%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Citigroup lifted their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. HSBC lifted their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. CICC Research started coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: RBC Capital Markets upgraded Pfizer to Sector Perform from Underperform, saying recent declines have reset valuation and reduced downside risk ahead of upcoming pipeline catalysts. Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
• Positive Sentiment: Pfizer received FDA support for an expanded use of HYMPAVZI in pediatric hemophilia patients, which strengthens the company’s rare disease growth narrative and broadens the drug’s commercial opportunity. PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
• Positive Sentiment: Pfizer also highlighted progress in its pipeline with updates on a next-generation pneumococcal shot and its mid-stage obesity program, reinforcing investor attention on future growth drivers beyond its legacy products. Pfizer’s Next-Gen Pneumococcal Shot: What a Fresh Trial Update Means for PFE Investors
• Positive Sentiment: Pfizer’s expanding obesity pipeline remains a potential long-term catalyst, as investors continue to look for a meaningful comeback story after the post-COVID revenue reset. Will obesity drugs save Pfizer from its post-COVID slump?
• Neutral Sentiment: Healthcare stocks overall fell late Wednesday, which likely added sector-level pressure on Pfizer even as company-specific news remained constructive. Sector Update: Healthcare Stocks Decline Late Afternoon
• Neutral Sentiment: Pfizer CEO Albert Bourla warned that German investment could be slowed or resized if drug-pricing proposals reduce returns, a reminder that pricing policy risk remains a headwind for the business. Pfizer CEO warns German investment at risk over drug pricing policies

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.